Tesofensine results: what to expect and when

An oral appetite drug with weight-loss trial results and heart-rate and psychiatric risks.

Also called: NS2330, NS-2330, NS 2330.

Fat-loss drugs · Serotonin, norepinephrine and dopamine reuptake inhibitor.

At least 22 distinct human studies identified. The sponsor reports 34 development trials; many lack public detail. Phase 3 registry results exist; long-term safety is unsettled.

Key studies

  • TIPO-1: obesity dose finding: Weight loss increased with dose; the safety record has reporting concerns. (source)
  • Mexico: phase 3 obesity trial: Registry results support weight loss; the full published safety dataset is missing. (source)
  • TIPO-4: long-term extension: Longer exposure occurred, but a complete final safety report was not found. (source)
  • TIPO appetite follow-up: Early satiety gains faded during continued use and returned after restarting. (source)
  • Two-week appetite and energy trial: Appetite changed clearly; total daily energy use did not significantly increase. (source)
  • Four neurology trials: pooled weight data: Unplanned weight loss led to obesity development. (source)

Related to Tesofensine

Sources

Sources checked: 2026-10-18.

Information only, not medical advice. Peptifacts does not sell anything and does not link to sellers.